LEADER 04374nam 22006855 450 001 9910765480003321 005 20240109000553.0 010 $a3-031-30065-3 024 7 $a10.1007/978-3-031-30065-3 035 $a(MiAaPQ)EBC30954305 035 $a(Au-PeEL)EBL30954305 035 $a(DE-He213)978-3-031-30065-3 035 $a(CKB)28887502900041 035 $a(EXLCZ)9928887502900041 100 $a20231117d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTargeting the DNA Damage Response for Cancer Therapy /$fedited by Timothy A. Yap, Geoffrey I. Shapiro 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (333 pages) 225 1 $aCancer Treatment and Research,$x2509-8497 ;$v186 311 08$aPrint version: Yap, Timothy A. Targeting the DNA Damage Response for Cancer Therapy Cham : Springer International Publishing AG,c2023 9783031300646 327 $aEvolution of the development of PARP inhibitors -- Exploiting cancer synthetic lethality in cancer ? Lessons learnt from PARP inhibitors -- Mechanisms of PARP inhibitor resistance -- Development of homologous recombination functional assays for targeting the DDR -- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer -- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer -- Development of PARP inhibitors in targeting castration-resistant prostate cancer -- Strategies for the management of patients with pancreatic cancer with PARP inhibitors -- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges -- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents -- Combining PARP inhibition and immunotherapy in BRCA-associated cancers -- Mitotic MTH1 inhibitors in treatment of cancer -- Targeting ATR in cancer medicine -- Targeting polymerase Theta (POLq) for cancer therapy -- Targeting DNA-PK -- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI). 330 $aThis book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic. Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis. 410 0$aCancer Treatment and Research,$x2509-8497 ;$v186 606 $aOncology 606 $aMedical radiology 606 $aPharmacology 606 $aDNA Repair 606 $aNeoplasms$xtherapy 606 $aPoly(ADP-ribose) Polymerase Inhibitors 606 $aDNA Repair Enzymes 606 $aOncology 606 $aRadiation Oncology 606 $aPharmacology 615 0$aOncology. 615 0$aMedical radiology. 615 0$aPharmacology. 615 2$aDNA Repair. 615 2$aNeoplasms$xtherapy. 615 2$aPoly(ADP-ribose) Polymerase Inhibitors. 615 2$aDNA Repair Enzymes. 615 14$aOncology. 615 24$aRadiation Oncology. 615 24$aPharmacology. 676 $a616.99406 676 $a616.99406 700 $aYap$b Timothy A$01448824 701 $aShapiro$b Geoffrey I$01448825 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910765480003321 996 $aTargeting the DNA Damage Response for Cancer Therapy$93644667 997 $aUNINA